Zevra Therapeutics appoints Wendy L. Dixon, Ph.D. to board of directors

ZEVRA THERAPEUTICS, INC.

Dr. Dixon appointed effective after April 25, 2023 annual meeting, filling vacancy from Dr. Travis Mickle's resignation.
She will serve as Class I director with term expiring at 2025 annual meeting.
Initial option grant of 22,500 shares vesting over three years; annual retainer of $40,000.
Dr. Dixon has over 40 years biopharma experience, previously CMO at Bristol Myers Squibb and SVP at Merck.
No family relationships or reportable transactions under Item 404(a) of Regulation S-K.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Travis Mickle

Director

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-04-25
Successor: Wendy L. Dixon
Filed: March 30, 2023, 7:59 PM ET

to fill the vacancy resulting from Dr. Travis Mickle's resignation from the Board effective as of that day.

Appointed

Wendy L. Dixon

Director

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-04-25
Filed: March 30, 2023, 7:59 PM ET

the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Wendy L. Dixon, Ph.D. to serve as a director of the Company, effective immediately following the conclusion of the Company’s 2023 Annual Meeting of Stockholders (the "2023 Annual Meeting") to be held on April 25, 2023, to fill the vacancy resulting from Dr. Travis Mickle's resignation from the Board effective as of that day.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Travis Mickle resigned as Director at ZEVRA THERAPEUTICS, INC..

Action: resigned
Role: Director

Exact text from the filing

to fill the vacancy resulting from Dr. Travis Mickle's resignation from the Board effective as of that day.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Wendy L. Dixon was appointed as Director at ZEVRA THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Wendy L. Dixon, Ph.D. to serve as a director of the Company, effective immediately following the conclusion of the Company’s 2023 Annual Meeting of Stockholders (the "2023 Annual Meeting") to be held on April 25, 2023, to fill the vacancy resulting from Dr. Travis Mickle's resignation from the Board effective as of that day.

View on SEC.gov

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-008527

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.